Hope in Focus: CFC3 and CFC4 Are Targeting the Root Cellular Causes of Glaucoma to Save Vision
The 2026 Research Progress Report from Glaucoma Research Foundation's Catalyst for a Cure.
GRF’s Catalyst for a Cure (CFC) initiatives have been shifting the paradigm of how we fight blindness since they began in 2002. Today, the brilliant minds of our CFC3 and CFC4 teams are breaking down the research silos that surround seemingly unrelated neurodegenerative diseases like glaucoma and Alzheimer’s. By collaborating across disciplines and sharing advanced technologies, these teams are unlocking groundbreaking therapies designed to better understand glaucoma and make vision restoration a reality.
CFC3: Vision Restoration Initiative
The CFC3 consortium—led by Drs. Xin Duan, Yang Hu, Anna La Torre, and Derek Welsbie—is focused on transplanting and protecting retinal ganglion cells (RGCs), the essential cells that link the eye to the brain.
- Cell Transplants: The team is testing how to transplant healthy RGCs to replace those that may be lost in glaucoma. They have discovered that reducing inflammation in the diseased eye environment is essential to help transplanted cells survive and integrate into the retina.
- Genetic Armor: Researchers demonstrated that shutting down specific enzymes provides powerful functional protection to RGCs.
- Visualizing Disease: By using high-tech spatial mapping, researchers are mapping individual eye cells across species to identify early biomarkers to help track glaucoma progression in real-time.
CFC4: The Initiative to Prevent and Cure Neurodegeneration
The Melza M. and Frank Theodore Barr Foundation Catalyst for a Cure to Prevent and Cure Neurodegeneration
The CFC4 team—spearheaded by Drs. Sandro Da Mesquita, Milica Margeta, Karthik Shekhar, and Humsa Venkatesh—is studying how the body’s immune system can actively drive—or prevent—damage to our neurons.
- Targeting the Root of Damage: The team discovered a brand-new population of immune cells located exactly where vision loss begins. In glaucoma, these cells become hyperactive and flood the area with inflammatory signals.
- Stopping Inflammation: Blocking this specific immune pathway successfully protected eye neurons from damage, showing that calming local inflammation can directly preserve vision.
- Learning from Cancer: Surprisingly, the team found that neurons exposed to inflammation in brain tumor models manage to survive. They are studying this phenomenon to borrow cancer’s “protective tools” to shield glaucoma patients’ vision.
What This Means for Patients
Rather than simply managing eye pressure, these discoveries target the root cellular causes of vision loss. Thanks to these discoveries, future glaucoma patients could benefit from earlier, more precise diagnostic testing, customized neuroprotective gene therapies, and innovative transplant procedures designed to restore lost sight.
Article by Cynthia Steel, PhD, MBA. Posted on September 10, 2026.
Pictured above: Members of the CFC3 and CFC4 research teams
Cynthia Steel, PhD
Cynthia Steel, PhD is the Chief Scientific Officer for Glaucoma Research Foundation. Her work is grounded in a commitment to improving patient outcomes and translating cutting-edge science into meaningful clinical applications.